A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401)

被引：0

作者：

Hironori Samura

Eiji Oki

Hiroshi Okumura

Takefumi Yoshida

Seiichiro Kai

Kazuma Kobayashi

Tatsuya Kinjo

Shinichiro Mori

Tetsuo Tohyama

Kippei Ohgaki

Hirofumi Kawanaka

Akitaka Makiyama

Norio Ureshino

Masahito Kotaka

Takayuki Shimose

Koji Ando

Hiroshi Saeki

Hideo Baba

Yoshihiko Maehara

Masaki Mori

机构：

[1] Urazoe General Hospital,Gastrointestinal Disease Center

[2] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences

[3] Kagoshima Koseiren Hospital,Department of Surgery

[4] Social Insurance Tagawa Hospital,Department of Surgery

[5] Nakatsu Municipal Hospital,Department of Surgery

[6] Nagasaki University Graduate School of Biomedical Sciences,Department of Surgery

[7] University of the Ryukyu Faculty of Medicine,Division of Digestive and General Surgery

[8] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Digestive Surgery, Breast and Thyroid Surgery

[9] Nakagami Hospital,Department of Surgery

[10] Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers,Department of Surgery

[11] National Hospital Organization Beppu Medical Center,Clinical Research Institute and Department of Surgery

[12] Japan Community Healthcare Organization Kyushu Hospital,Department of Hematology/Oncology

[13] Gifu University Hospital,Cancer Center

[14] Department of Medical Oncology,Gastrointestinal Cancer Center

[15] Sano Hospital,Department of General Surgical Science Graduate School of Medicine

[16] Clinical Research Support Center Kyushu,Department of Gastroenterological Surgery, Graduate School of Medical Sciences

[17] Gunma University,undefined

[18] Kumamoto University,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2020年 / 86卷

关键词：

Metastatic colorectal cancer; Cetuximab; S-1; Irinotecan; Oral fluoropyrimidine;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：285 / 294

页数：9

共 512 条

[11]

Ishihara S(2012)ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making Ann Oncol 23 2479-152

[12]

Kanemitsu Y(2013)Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines J Natl Compr Canc Netw 11 141-239

[13]

Kinugasa Y(2015)Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer Int J Clin Oncol 20 207-1546

[14]

Murofushi K(2016)Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) Ann Oncol 27 1539-3116

[15]

Nakajima TE(2009)Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 3109-1058

[16]

Oka S(2011)Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104–a randomized trial of the German AIO CRC study group J Clin Oncol 29 1050-459

[17]

Tanaka T(2012)Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) Br J Cancer 106 453-357

[18]

Taniguchi H(2007)Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results Am J Clin Oncol 30 350-1587

[19]

Tsuji A(2013)Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group Ann Oncol 24 1580-2606

[20]

Uehara K(1996)Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 2602-860

← 1 2 3 4 5 6 7 8 9 10 →